Milestone Scientific Inc. income statement
In fiscal 2025, Milestone Scientific Inc. reported revenue of $9.0m, up 4.0% on the year before, operating income of −$5.7m (a -63.5% margin) and net income of −$5.7m, or −$0.07 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.
Income statement
| Fiscal year | 2010Dec 2010 | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 10 | 8 | 9 | 10 | 10 | 9 | 10 | 11 | 10 | 8 | 5 | 10 | 9 | 10 | 9 | 9 | 9 |
| Cost of revenue | — | — | — | — | — | — | — | 4 | 5 | 3 | 2 | 4 | 4 | 3 | 2 | 3 | 3 |
| Gross profit | 6 | 5 | 6 | 7 | 7 | 6 | 6 | 7 | 4 | 6 | 4 | 6 | 5 | 7 | 6 | 6 | 7 |
| Research and development | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | — |
| Selling, general and administrative | 7 | 6 | 6 | 6 | 7 | 9 | 12 | 12 | 11 | 10 | 11 | 13 | 13 | 13 | 12 | 12 | 11 |
| Operating income | −1 | −1 | −1 | 1 | −1 | −3 | −7 | −5 | −8 | −4 | −7 | −7 | −9 | −7 | −7 | −6 | −4 |
| Interest expense | 0 | 0 | 0 | 0 | 0 | — | — | — | — | — | — | — | — | — | — | — | — |
| Net interest income | — | — | — | — | — | — | — | — | 0 | 0 | −0 | −0 | 0 | 0 | 0 | — | — |
| Income before tax | — | — | — | 1 | −2 | −3 | −7 | −5 | −8 | −8 | −7 | −7 | −9 | −7 | −5 | −6 | −4 |
| Income tax | — | — | — | — | 0 | 0 | −0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | — | — |
| Net income | −1 | −1 | −1 | 1 | −2 | −5 | −6 | −5 | −7 | −8 | −7 | −7 | −9 | −7 | −5 | −6 | −4 |
| Diluted EPS | — | −$0.10 | −$0.05 | $0.08 | −$0.08 | −$0.26 | −$0.22 | −$0.16 | −$0.21 | −$0.16 | −$0.12 | −$0.10 | — | — | −$0.06 | −$0.07 | −$0.05 |
| Diluted shares (average) | — | 15m | 16m | 17m | 20m | 21m | 27m | 33m | 35m | 46m | 63m | 69m | 71m | 73m | 80m | 82m | 86m |
| EBITDA | −1 | −1 | −1 | 1 | −1 | −3 | −6 | −5 | −7 | −4 | −7 | −7 | −9 | −7 | −7 | −6 | −4 |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2,514 | 2,014 | 2,232 | 2,323 | 2,360 | 2,058 | 2,162 | 2,841 |
| Cost of revenue | 678 | 502 | 585 | 706 | 719 | 556 | 598 | 931 |
| Gross profit | 1,836 | 1,511 | 1,647 | 1,618 | 1,641 | 1,502 | 1,564 | 1,910 |
| Research and development | 232 | 218 | 369 | 52 | 16 | 12 | — | 7 |
| Selling, general and administrative | 3,065 | 3,327 | 3,257 | 3,031 | 2,739 | 2,550 | 2,373 | 2,946 |
| Operating income | −1,469 | −2,042 | −1,998 | −1,485 | −1,134 | −1,080 | −828 | −1,062 |
| Net interest income | 8 | 7 | 3 | 2 | — | — | — | — |
| Income before tax | −1,461 | −2,036 | −1,995 | −1,483 | −1,154 | −1,091 | −840 | −1,059 |
| Income tax | — | — | — | 0 | — | — | — | — |
| Net income | −1,461 | −2,036 | −1,995 | −1,483 | −1,154 | −1,091 | −840 | −1,059 |
| Diluted EPS | −$0.02 | −$0.03 | −$0.02 | −$0.02 | −$0.01 | −$0.01 | −$0.01 | −$0.01 |
| EBITDA | −1,461 | −2,034 | −1,978 | −1,465 | −1,114 | −1,061 | −809 | −1,042 |
Compare with peers
- Neuroone Medical Technologies Corp income statement
- Nuwellis, Inc. income statement
- Work Medical Technology Group LTD income statement
- Anbio Biotechnology income statement
- Inspiremd, Inc. income statement
Head to head: MLSS vs NMTCMLSS vs NUWEMLSS vs WOKMLSS vs NNNN
More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies